What is the needle‑stick exposure protocol for hepatitis B surface antigen (HBsAg) and human immunodeficiency virus (HIV)?

Needlestick Protocol for HBsAg and HIV

Immediately wash the wound with soap and water (or flush mucous membranes with water), then rapidly test the source patient for HBsAg and HIV antibody using rapid testing if available, assess the exposed person's hepatitis B immunity status, and initiate appropriate postexposure prophylaxis (PEP) within hours of exposure based on the source's infection status and the exposed person's vaccination history. 1

Immediate Wound Care

First, provide immediate care to the exposure site 1:

• Wash wounds and skin with soap and water
• Flush mucous membranes with water
• Do NOT squeeze or manipulate the wound excessively

Risk Assessment

Determine the exposure risk by evaluating 1:

Type of exposure:

• Percutaneous injury (needlestick, cut with sharp object)
• Mucous membrane exposure
• Nonintact skin exposure
• Bites resulting in blood exposure

Type of fluid:

• Blood or visibly bloody fluid (highest risk)
• Other potentially infectious fluids
• Concentrated virus

Source Patient Evaluation

Test the source patient immediately for 1, 2:

• HBsAg (hepatitis B surface antigen)
• HIV antibody (consider rapid testing for faster results)
• Anti-HCV (though HCV PEP is not recommended)

Critical caveat: Do NOT test discarded needles or syringes for virus contamination—this is unreliable and wastes time 1, 2.

Exposed Person Evaluation

Assess the exposed healthcare worker's 1:

• Hepatitis B vaccination history
• Anti-HBs antibody status (documented vaccine response)
• Pregnancy status (for women of childbearing age if HIV PEP is being considered)

Hepatitis B Postexposure Prophylaxis

The HBV PEP decision depends on both the exposed person's vaccination/antibody status AND the source's HBsAg status 2:

If Source is HBsAg Positive:

• Unvaccinated exposed person: Give hepatitis B vaccine series + HBIG (0.06 mL/kg IM) immediately
• Previously vaccinated with known adequate response (anti-HBs ≥10 mIU/mL): No treatment needed
• Previously vaccinated with known inadequate response (nonresponder): Give HBIG × 1 and reinitiate vaccine series OR give HBIG × 2
• Previously vaccinated with unknown antibody response: Test exposed person for anti-HBs immediately
  • If adequate (≥10 mIU/mL): No treatment
  • If inadequate (<10 mIU/mL): Give HBIG × 1 and vaccine booster

If Source is HBsAg Negative:

• Unvaccinated: Initiate hepatitis B vaccine series
• Vaccinated: No treatment needed

If Source is Unknown or Unavailable:

• If known high-risk source: Treat as if HBsAg positive
• Otherwise: Follow same algorithm as HBsAg negative

HIV Postexposure Prophylaxis

HIV PEP must be initiated as soon as possible, ideally within hours of exposure, and continued for 4 weeks if tolerated 1, 2.

Decision Algorithm for HIV PEP:

For percutaneous injuries 2:

• Less severe exposure (solid needle, superficial injury):

  • HIV-positive source (Class 1: asymptomatic or low viral load): Recommend basic 2-drug PEP
  • HIV-positive source (Class 2: symptomatic, AIDS, high viral load): Recommend expanded 3-drug PEP

• More severe exposure (large-bore hollow needle, deep puncture, visible blood on device, needle used in source's artery/vein):

  • HIV-positive source (any class): Recommend expanded 3-drug PEP

• Unknown HIV status source with risk factors: Consider basic 2-drug PEP

• HIV-negative source: No PEP warranted

Basic 2-Drug Regimen 1:

• Zidovudine (ZDV/AZT) 600 mg daily in 2-3 divided doses + Lamivudine (3TC) 150 mg twice daily
• Available as combination tablet (Combivir) twice daily
• This regimen has demonstrated decreased HIV transmission risk in case-control studies

Expanded 3-Drug Regimen:

• Basic regimen plus a third antiretroviral (consult expert for selection based on source virus resistance patterns)

Critical timing: Evaluate exposed persons taking PEP within 72 hours after exposure and monitor for drug toxicity at least every 2 weeks 1.

Follow-Up Testing

For HBV Exposures 1:

• Test for anti-HBs 1-2 months after the last vaccine dose in persons who received hepatitis B vaccine
• Note: Anti-HBs response cannot be accurately assessed if HBIG was given in the previous 3-4 months

For HIV Exposures 1:

• HIV antibody testing at baseline, 6 weeks, 3 months, and 6 months postexposure
• Test immediately if acute retroviral syndrome symptoms develop (fever, rash, myalgias, lymphadenopathy)
• Advise precautions to prevent secondary transmission during the 6-month follow-up period

For HCV Exposures 1:

• Baseline and follow-up anti-HCV and ALT testing at 4-6 months
• HCV RNA at 4-6 weeks if earlier diagnosis desired
• No PEP is recommended for HCV 1, 2

Common Pitfalls to Avoid

1. Delaying HIV PEP: Every hour counts—initiate within hours, not days
2. Testing discarded needles: This is explicitly not recommended and wastes critical time 1
3. Assuming all vaccinated persons are protected: Always verify anti-HBs status or treat empirically if unknown
4. Forgetting pregnancy testing: Required before initiating HIV PEP in women of childbearing age 2
5. Poor adherence monitoring: Side effects from HIV PEP are common—provide antimotility and antiemetic agents proactively 1
6. Inadequate counseling: Address psychological distress, which affects 87% of exposed workers 3

The evidence base for these protocols comes from the 2001 U.S. Public Health Service guidelines, which remain the foundational guidance for occupational bloodborne pathogen exposures 1, 2. While these guidelines are from 2001, they represent comprehensive consensus recommendations that continue to guide practice, though individual institutions may have updated antiretroviral regimens based on newer agents.